It is well known that translocation between chromosomes 2 and 8, t(2;8)(p12;q24), has a strong association with Burkitt’s lymphoma. It has rarely been seen in indolent lymphoproliferative disorders. In this study, we report for the first time on 2 cases of chronic lymphocytic leukemia (CLL) with t(2;8). They were diagnosed as having typical CLL (case 1) and CLL/prolymphocytic leukemia (case 2), respectively, based on morphology and immunophenotyping. Karyotypic analysis of the bone marrow cells using the R-banding technique revealed a karyotype of 47,XY, t(2;8)(p12;q24), +4,[17]/46, XY[9] in case 1 and a karyotype of 45,X, t(Y;7)(q12;q21),t(2;8)(p12; q24),del(12)(p12),–17[5]/46,XY[9] in case 2. T(2;8) translocation was confirmed by whole chromosome painting. Rearrangement of the MYC gene and loss of one p53 allele were detected by FISH only in case 2. Both cases had negative ZAP70 and CD38 expressions; however, only case 1 showed good response to therapy. We consider that MYC rearrangement, loss of one p53 allele as well as other factors, such as more prolymphocytes in the blood and bone marrow and complex chromosome abnormalities, also had adverse effects on the poorer prognosis of case 2.

Keywords:
Burkitt lymphoma, Chromosome translocation, Chronic lymphocytic leukemia, Fluorescence in situ hybridization
1.
Croce CM, Nowell PC: Molecular basis of human B cell neoplasia. Blood 1985;65:1–7.
2.
Dalla-Favera R, Martinotti S, Gallo RC, Erikson J, Croce CM: Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas. Science 1983;4587:963–967.
3.
Mitelman F, Johansson B, Mertens F (eds): Mitelman database of chromosome aberrations in cancer. 2008. http://cgap.nci.nih.gov/Chromosomes/RecurrentAberrations.
4.
Cory S: Activation of cellular oncogenes in hemopoietic cells by chromosome translocation. Adv Cancer Res 1986;47:189–234.
5.
Juliusson G, Oscier DG, Fitchett M, Ross FM, Stockdill G, Mackie MJ, Parker AC, Castoldi GL, Guneo A, Knuutila S, Elonen E, Gahrton G: Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990;323:720–724.
6.
Asou N, Osato M, Horikawa K, Nishikawa K, Sakitani O, Li L, Yamasaki H, Nishimura S, Okubo T, Suzushima H, Takatsuki K: Burkitt’s type acute lymphoblastic transformation associated with t(8;14) in a case of B cell chronic lymphocytic leukemia. Leukemia 1997;11:1986–1988.
7.
Fleischman EW, Prigogina EL: Karyotype peculiarities of malignant lymphomas. Hum Genet 1977;35:269–279.
8.
Levine EG, Arthur DC, Frizzera G, Peterson BA, Hurd DD, Bloomfield CD: There are differences in cytogenetic abnormalities among histologic subtypes of the non-Hodgkin’s lymphomas. Blood 1985;66:1414–1422.
9.
Mark HF, Sotomayor E, Mega A: Occurrence of both t(1;19) and t(8;14) in a patient with chronic lymphocytic leukemia. Exp Mol Pathol 1999;66:238–242.
10.
Palka G, Fioritoni G, Lombardo M, Donti E, Calabrese G, Stuppia L, Di Marco G, Guanciali Franchi P, Parruti G, Geraci L: Chromosome abnormalities in PHA-stimulated and non stimulated bone marrow cultures from patients with non Hodgkin lymphoma. Haematologica 1988;73:489–494.
11.
Reddy KS: Chronic lymphocytic leukaemia profiled for prognosis using a fluorescence in situ hybridisation panel. Br J Haematol 2006;132:705–722.
12.
Reddy K, Satyadev R, Bouman D, Hibbard MK, Lu G, Paolo R: Burkitt t(8;14)(q24;q32) and cryptic deletion in a CLL patient: report of a case and review of literature. Cancer Genet Cytogenet 2006;166:12–21.
13.
Juliusson G, Friberg K, Gahrton G: Consistency of chromosomal aberrations in chronic B-lymphocytic leukemia. A longitudinal cytogenetic study of 41 patients. Cancer 1988;62:500–506.
14.
Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848–1854.
15.
Hsiao HH, Hung YH, Hsiao HP, Tseng SB, Tsai HJ, Liu YC, Liu TC, Chao MC, Chang Y, Lin SF: Case of chronic lymphocytic leukemia with unusual chromosome aberrations. Int J Hematol 2004;80:351–355.
16.
Merchant S, Schlette E, Sanger W, Lai R, Medeiros LJ: Mature B-cell leukemias with more than 55% prolymphocytes: report of 2 cases with Burkitt lymphoma-type chromosomal translocations involving c-myc. Arch Pathol Lab Med 2003;127:305–309.
17.
Solé F, Woessner S, Pérez-Losada A, Florensa L, Montero S, Asensio A, Besses C, Sans-Sabrafen J: Cytogenetic studies in seventy-six cases of B-chronic lymphoproliferative disorders. Cancer Genet Cytogenet 1997;93:160–166.
18.
Struski S, Leymarie V, Helias C, Falkenrodt A, Fohrer C, Audhuy B, Lioure B, Moskovtchenko P, Mazurier I, Galoisy AC, Gervais C, Mauvieux L, Herbrecht R, Bergerat JP, Lessard M: A cytological, immunophenotypical and cytogenetical study of 136 consecutive cases of B-cell chronic lymphoid hemopathies (in French). Pathol Biol (Paris) 2007;55:59–72.
19.
Xue Y, Yu F, Zhou Z, He Z, Guo Y, Wang M, Lin B: Complex karyotypic abnormalities including t(8;22) in a patient with chronic lymphocytic leukemia. Cancer Genet Cytogenet 1993;65:157–160.
20.
Mohamed AN, Compean R, Dan ME, Smith MR, Al-Katib A: Clonal evolution of chronic lymphocytic leukemia to acute lymphoblastic leukemia. Cancer Genet Cytogenet 1996;86:143–146.
21.
Litz CE, Arthur DC, Gajl-Peczalska KJ, Rausch D, Copenhaver C, Coad JE, Brunning RD: Transformation of chronic lymphocytic leukemia to small non-cleaved cell lymphoma: a cytogenetic, immunological and molecular study. Leukemia 1991;5:972–978.
22.
Shaffer LG, Tommerup N: ISCN 2005: An International System for Human Cytogenetics Nomenclature. Basel, Karger, 2005.
23.
Li T, Xue Y, Wu Y, Pan J: Clinical and molecular cytogenetic studies in seven patients with myeloid diseases characterized by i(20q-). Br J Haematol 2004;125:337–342.
24.
Catovsky D, Montserrat E, Müller-Hermelink HK, Harris NL: B-cell prolymphocytic leukaemia; in Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): Tumours of Haemopoetic and Lymphoid Tissues: World Health Organization Classification of Tumors. Lyon, IARC Press, 2001, pp 131–132.
25.
DiGiuseppe JA, Borowitz MJ: Clinical utility of flow cytometry in the chronic lymphoid leukemias. Semin Oncol 1998;25:6–10.
26.
Robert KH: PHA-induced soluble factor(s) can activate B-cells from patients with chronic lymphatic leukaemia. Clin Exp Immunol 1979;37:517–522.
27.
Magrath I: The pathogenesis of Burkitt’s lymphoma. Adv Cancer Res 1990;55:133–270.
28.
Blyth K, Terry A, O’Hara M, Baxter EW, Campbell M, Stewart M, Donehower LA, Onions DE, Neil JC, Cameron ER: Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss. Oncogene 1995;10:1717–1723.
29.
Wong KF, Kwong YL, Hui PK: Hairy cell leukemia variant with t(2;8)(p12;q24) abnormality. Cancer Genet Cytogenet 1997;98:102–105.
30.
Potti A, Panwalkar A, Ingebretson MC, Tharapel SA, Goodell M, Dayton MV, Mehdi SA: An indolent B-cell lymphoma with t(2;8)(p12;q24) abnormality and absence of C-MYC amplification and TP53 deletion: a new variant? Cancer Genet Cytogenet 2003;144:76–79.
31.
Schroers R, Griesinger F, Trümper L, Haase D, Kulle B, Klein-Hitpass L, Sellmann L, Dührsen U, Dürig J: Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 2005;19:750–758.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.